---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-22-000005"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2022-02-07T23:59:59+00:00"
generated_at: "2026-06-27T10:50:52.473465+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amgen Q4 non-GAAP EPS $4.36, up 26% YoY; full-year revenue $26.0B (+2%)

## Summary
- Q4 total revenues $6.8B (+3% YoY); product sales -1% but volumes up for Prolia, Repatha, MVASI, EVENITY.
- GAAP EPS $3.36 (+22% Q4); full-year GAAP EPS $10.28 (-16%) due to $1.5B Five Prime IPR&D write-off.
- Non-GAAP EPS $4.36 Q4 (+26%), full-year $17.10 (+6%); non-GAAP operating margin 51.1%.
- Full-year free cash flow $8.4B, down from $9.9B due to 2020 swap monetization and capex timing.
- Quarterly dividend raised to $1.76/share, up 10% YoY (full-year $7.04, +10%).

## SEC filing metadata
- accession: 0000318154-22-000005
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2022-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815422000005/0000318154-22-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815422000005/amgn-20220207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-22-000005
- JSON: https://secwatch.observer/filing/0000318154-22-000005.json
- Plain text: https://secwatch.observer/filing/0000318154-22-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.